North America Hematuria Treatment Market

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Analysis By Treatment (Drugs, Therapies, and Others), Indication (Urinary Tract Infections, Kidney Stones, Urethritis, Blood Cancer, Bladder Stones, Prostate Cancer, Cystitis, Trauma, Vigorous Exercise, Polycystic Kidney Disease, Endometriosis, and Menstruation), Type (Macroscopic Hematuria, Microscopic Hematuria, Idiopathic Hematuria, and Jogger’s Hematuria), End User (Hospitals, Clinics, and Ambulatory Surgical Centers, and Others)


No. of Pages: 158    |    Report Code: TIPRE00026252    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Buy Now
North America Hematuria Treatment Market
Buy Now

Market Introduction

Hematuria is a medical condition where presence of blood is found in the urine. Generally, urine does not contain RBC and hence this can result in serious issue that may also cause kidney stones, urinary tract infection and other inherited diseases.

Moreover, the high prevalence hematuria associated indications is expected to bolster the market growth during the forecast period. However, undiagnosed cases of associated indications limit the growth of the North America hematuria treatment market.

The pandemic has offered vital growth opportunities for the players operating in the kidney disease market. The possibilities were due to the rising numbers of patients affected by the coronavirus. For instance, according to the American Society of Nephrology report, in response to COVID-19, half coronavirus positive patients admitted to intensive care unit (ICU) experience kidney failure that requires some form of dialysis. The report stated that ~ 10% to 50% of patients in ICU showed kidney failure, nearly 17% of patients needed urgent dialysis, and 46% had shown some forms of acute kidney injury (AKI). Across the North American region, the US has registered the highest numbers of patients affected by the coronavirus. Thus, the rising numbers of patients are at higher risk of getting affected for acute kidney injury (AKI), including tubular injury with septic shock, micro-inflammation, increased blood clotting, and probable direct infection of the kidney. Therefore, it is expected to raise the demand for kidney disease management products leading to market growth in the coming future.


Get more information on this report

North America Hematuria Treatment Strategic Insights

Strategic insights for the North America Hematuria Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/north-america-hematuria-treatment-market-strategic-framework.webp
Get more information on this report

North America Hematuria Treatment Report Scope

Report Attribute Details
Market size in 2021 US$ 351.6 Million
Market Size by 2028 US$ 419.7 Million
Global CAGR (2021 - 2028) 2.6%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Treatment
  • Drugs
  • Therapies
By Indication
  • Urinary Tract Infections
  • Kidney Stones
  • Urethritis
  • Blood Cancer
  • Bladder Stones
  • Prostate Cancer
  • Cystitis
  • Trauma
  • Vigorous Exercise
  • Polycystic Kidney Disease
  • Endometriosis
  • Menstruation
By Type
  • Macroscopic Hematuria
  • Microscopic Hematuria
  • Idiopathic Hematuria
  • Jogger's Hematuria
By End User
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Market leaders and key company profiles
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • F. HOFFMANN-LA ROCHE LTD.
  • GlaxoSmithKline plc.
  • Janssen Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Boehringer Ingelheim International GmbH
  • Get more information on this report

    North America Hematuria Treatment Regional Insights

    The geographic scope of the North America Hematuria Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

    geography/north-america-hematuria-treatment-market-geography.webp
    Get more information on this report


    Market Overview and Dynamics

    The North America hematuria treatment market is projected to reach US$ 419.7 million by 2028 from US$ 351.6 million in 2021; it is anticipated to grow at a CAGR of 2.6% from 2021 to 2028. Technological developments in medical devices and diagnostic procedures have led to various options for managing hematuria-associated indications, such as kidney stones, bladder stones, and urinary tract infections. The use of advanced treatment technologies is expected to enhance patient care. For instance, the implementation of robotics in surgeries for treating urolithiasis has gained popularity in recent years. Currently, Vinci Surgical System, by Intuitive Surgical Inc., is widely used in performing surgeries to treat urolithiasis. Similarly, the uptake of endourological interventions for kidney stones has increased significantly across various countries. It is also expected that advancements in associated indications are likely to support the North America hematuria treatment market during the forecast period.

    Key Market Segments

    In terms of type, the macroscopic hematuria segment accounted for the largest share of the North America hematuria treatment market in 2020. In terms of treatment, the drugs segment accounted for the largest share of the North America hematuria treatment market in 2020. In terms of indication, the urinary tract infection segment accounted for the largest share of the North America hematuria treatment market in 2020. In terms of end user, the hospitals segment accounted for the largest share of the North America hematuria treatment market in 2020.

    Major Sources and Companies Listed

    A few major primary and secondary sources referred to for preparing this report on the hematuria treatment market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, and Boehringer Ingelheim International GmbH.

    Reasons to Buy Report

    • To understand the North America hematuria treatment market landscape and identify market segments that are likely to guarantee a strong return
    • To comprehend the ever-changing market landscape and stay ahead in competition
    • To efficiently plan merger and acquisition, and partnership deals in the North America hematuria treatment market by identifying segments with the most promising probable sales
    • To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
    • To obtain market revenue forecast of the North America hematuria treatment market based on various segments for the period 2021–2028

    NORTH AMERICA HEMATURIA TREATMENT MARKET SEGMENTATION

    By

    Treatment

    • Drugs
    • Therapies
    • Others

    By Indication

    • Urinary Tract Infections
    • Kidney Stones
    • Urethritis
    • Blood Cancer
    • Bladder Stones
    • Prostate Cancer
    • Cystitis
    • Trauma
    • Vigorous Exercise
    • Polycystic Kidney Disease
    • Endometriosis
    • Menstruation

    By Type

    • Macroscopic Hematuria
    • Microscopic Hematuria
    • Idiopathic Hematuria
    • Jogger’s Hematuria

    By End User

    • Hospitals
    • Clinics
    • Ambulatory Surgical Centers (ASC's)
    • Others

    By Country

    • North America
    • US
    • Canada
    • Mexico

    Companies Mentioned

    • AstraZeneca
    • Bristol-Myers Squibb Company
    • F. HOFFMANN-LA ROCHE LTD.
    • GlaxoSmithKline plc.
    • Janssen Pharmaceuticals
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd
    • Boehringer Ingelheim International GmbH 

    The List of Companies - North America Hematuria Treatment Market

    1. AstraZeneca
    2. Bristol-Myers Squibb Company
    3. F. HOFFMANN-LA ROCHE LTD.
    4. GlaxoSmithKline plc.
    5. Janssen Pharmaceuticals
    6. Merck & Co., Inc.
    7. Novartis AG
    8. Pfizer Inc.
    9. Sun Pharmaceutical Industries Ltd
    10. Boehringer Ingelheim International GmbH
    Frequently Asked Questions
    How big is the North America Hematuria Treatment Market?

    The North America Hematuria Treatment Market is valued at US$ 351.6 Million in 2021, it is projected to reach US$ 419.7 Million by 2028.

    What is the CAGR for North America Hematuria Treatment Market by (2021 - 2028)?

    As per our report North America Hematuria Treatment Market, the market size is valued at US$ 351.6 Million in 2021, projecting it to reach US$ 419.7 Million by 2028. This translates to a CAGR of approximately 2.6% during the forecast period.

    What segments are covered in this report?

    The North America Hematuria Treatment Market report typically cover these key segments-

    • Treatment (Drugs, Therapies)
    • Indication (Urinary Tract Infections, Kidney Stones, Urethritis, Blood Cancer, Bladder Stones, Prostate Cancer, Cystitis, Trauma, Vigorous Exercise, Polycystic Kidney Disease, Endometriosis, Menstruation)
    • Type (Macroscopic Hematuria, Microscopic Hematuria, Idiopathic Hematuria, Jogger's Hematuria)
    • End User (Hospitals, Clinics, Ambulatory Surgical Centers)

    What is the historic period, base year, and forecast period taken for North America Hematuria Treatment Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Hematuria Treatment Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in North America Hematuria Treatment Market?

    The North America Hematuria Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • AstraZeneca
  • Bristol-Myers Squibb Company
  • F. HOFFMANN-LA ROCHE LTD.
  • GlaxoSmithKline plc.
  • Janssen Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Boehringer Ingelheim International GmbH
  • Who should buy this report?

    The North America Hematuria Treatment Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the North America Hematuria Treatment Market value chain can benefit from the information contained in a comprehensive market report.